

Valentina Garibotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8340864/publications.pdf>

Version: 2024-02-01

223
papers

6,676
citations

76196

40
h-index

79541

73
g-index

260
all docs

260
docs citations

260
times ranked

8113
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. <i>Journal of Neurochemistry</i> , 2023, 164, 346-363.	2.1	10
2	Description of a European memory clinic cohort undergoing amyloid- β PET: The AMYPAD Diagnostic and Patient Management Study. <i>Alzheimer's and Dementia</i> , 2023, 19, 844-856.	0.4	6
3	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 563-584.	3.3	41
4	2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1090-1091.	3.3	7
5	Lifelong bilingualism and mechanisms of neuroprotection in Alzheimer dementia. <i>Human Brain Mapping</i> , 2022, 43, 581-592.	1.9	7
6	Case 15: Non-lesional Temporal Epilepsy. , 2022, , 77-81.		0
7	Low-Dose Radiation Therapy Reduces Amyloid Load in Young 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 641-653.	1.2	16
8	Personality Impact on Alzheimer's Disease "Signature and Vascular Imaging Markers: A PET-MRI Study. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1807-1817.	1.2	5
9	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34
10	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2106-2112.	3.3	5
11	SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 113, 73-83.	1.5	2
12	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651.	3.3	82
13	The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid/Tau-PET and MR Imaging. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	1.2	2
14	Impact of cerebral blood flow and amyloid load on SUVR bias. <i>EJNMMI Research</i> , 2022, 12, 29.	1.1	6
15	Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. <i>Diagnostics</i> , 2022, 12, 1665.	1.3	11
16	Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2021, 32, 102791.	1.4	2
17	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2200-2211.	3.3	19
18	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European- β DLB consortium project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1277-1286.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	3.3	33
20	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	3.3	18
21	Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2067-2069.	3.3	5
22	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2021, 17, 1186-1194.	0.7	4
23	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	3.6	27
24	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	3.3	11
25	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	3.3	22
26	Finding our way through the labyrinth of dementia biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2320-2324.	3.3	5
27	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 105.	3.0	15
28	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036.	3.3	6
29	Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model. <i>Neurobiology of Aging</i> , 2021, 103, 117-127.	1.5	19
30	Prediction of Subtle Cognitive Decline in Normal Aging: Added Value of Quantitative MRI and PET Imaging. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 664224.	1.7	0
31	PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 742093.	1.3	8
32	Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus: Linking Functional Connectivity and Clinical Outcome. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1-12.	1.2	8
33	Clinical Characterization of Atypical Primary Progressive Aphasia in a 3-Year Longitudinal Study: A Case Report. <i>Cognitive and Behavioral Neurology</i> , 2021, 34, 233-244.	0.5	2
34	PET Imaging in Neurodegeneration and Neuro-oncology: Variants and Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 408-418.	2.5	15
35	Determinants of Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study in a Community-based Cohort. <i>Current Alzheimer Research</i> , 2021, 18, 482-491.	0.7	3
36	Appropriate use criteria for dementia amyloid imaging in Switzerland – mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics. <i>Nuklearmedizin - Nuclear Medicine</i> , 2021, 60, 7-9.	0.3	2

#	ARTICLE	IF	CITATIONS
37	PET imaging in dementia. , 2021, , .		0
38	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 187.	3.0	29
39	Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer's Disease and Neurodegeneration: Old Drugs, New Concerns. <i>Frontiers in Oncology</i> , 2021, 11, 734881.	1.3	3
40	Towards fingerprinting and identifiability within the Alzheimer's continuum using resting-state functional connectivity. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Feeling of presence in dementia with Lewy bodies is related to reduced left frontoparietal metabolism. <i>Brain Imaging and Behavior</i> , 2020, 14, 1199-1207.	1.1	7
42	Nicotinic Acetylcholine Receptor Density in the "Higher-Order" Thalamus Projecting to the Prefrontal Cortex in Humans: a PET Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 417-424.	1.3	7
43	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 270-280.	3.3	23
44	Projection Space Implementation of Deep Learning "Guided Low-Dose Brain PET Imaging Improves Performance over Implementation in Image Space. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1388-1396.	2.8	66
45	Basal forebrain metabolism in Alzheimer's disease continuum: relationship with education. <i>Neurobiology of Aging</i> , 2020, 87, 70-77.	1.5	15
46	Determinants of mesial temporal lobe volume loss in older individuals with preserved cognition: a longitudinal PET amyloid study. <i>Neurobiology of Aging</i> , 2020, 87, 108-114.	1.5	9
47	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
48	The A/T/N model applied through imaging biomarkers in a memory clinic. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 247-255.	3.3	23
49	Localizing non-epileptiform abnormal brain function in children using high density EEG: Electric Source Imaging of focal slowing. <i>Epilepsy Research</i> , 2020, 159, 106245.	0.8	12
50	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254
51	Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 38-43.	1.1	10
52	COVID-19 and the brain: impact on nuclear medicine in neurology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2487-2492.	3.3	18
53	PET amyloid in normal aging: direct comparison of visual and automatic processing methods. <i>Scientific Reports</i> , 2020, 10, 16665.	1.6	8
54	In Vivo TSPO Signal and Neuroinflammation in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1941.	1.8	51

#	ARTICLE	IF	CITATIONS
55	Microbleeds and Medial Temporal Atrophy Determine Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1431-1442.	1.2	10
56	Alzheimer's disease biomarker roadmap 2020: [18 F]flortaucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.4	0
57	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.4	1
58	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.4	2
59	In vivo imaging of locus coeruleus integrity at ultra-high field: A feasibility study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040835.	0.4	0
60	Extrastriatal dopaminergic and serotonergic pathways in Alzheimer's disease: A 123 I- ¹²³ I-FP-CIT study. <i>Alzheimer's and Dementia</i> , 2020, 16, e041317.	0.4	0
61	Low-dose radiation therapy: A new potential treatment targeting amyloid load and neuroinflammation in an AD rat model. <i>Alzheimer's and Dementia</i> , 2020, 16, e042402.	0.4	0
62	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e042628.	0.4	1
63	Imaging dopamine system transporter activity and connectivity in Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043304.	0.4	1
64	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045436.	0.4	1
65	The biomarker roadmap for the validation for Alzheimer's biomarkers: Methodological update for biomarkers of tauopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e039063.	0.4	3
66	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
67	Assessment of Lesion Detectability in Dynamic Whole-Body PET Imaging Using Compartmental and Patlak Parametric Mapping. <i>Clinical Nuclear Medicine</i> , 2020, 45, e221-e231.	0.7	21
68	Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson's disease – the PPMI cohort. <i>BMC Neurology</i> , 2020, 20, 192.	0.8	13
69	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	3.3	134
70	3D printing for dosimetric optimization and quality assurance in small animal irradiations using megavoltage X-rays. <i>Zeitschrift Fur Medizinische Physik</i> , 2020, 30, 227-235.	0.6	4
71	Highlights of the 32th Annual Congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine – a global competition for excellence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1808-1819.	3.3	5
72	Preserved Extrastriatal 123I-FP-CIT Binding in Scans Without Evidence of Dopaminergic Deficit (SWEDD). <i>Molecular Imaging and Biology</i> , 2020, 22, 1592-1599.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Deep learning-guided joint attenuation and scatter correction in multitracer neuroimaging studies. <i>Human Brain Mapping</i> , 2020, 41, 3667-3679.	1.9	52
74	Proven validity and management impact of amyloid imaging in Alzheimer's disease"repetita juvant. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1787-1790.	3.3	1
75	Higher availability of $\alpha_4\beta_2$ nicotinic receptors (nAChRs) in dorsal ACC is linked to more efficient interference control. <i>NeuroImage</i> , 2020, 214, 116729.	2.1	6
76	Less agreeable, better preserved? A PET amyloid and MRI study in a community-based cohort. <i>Neurobiology of Aging</i> , 2020, 89, 24-31.	1.5	11
77	A kinetics-based approach to amyloid PET semi-quantification. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2175-2185.	3.3	3
78	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 112-125.	0.7	40
79	Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 411-419.	1.2	21
80	PET Imaging of Dopamine Neurotransmission During EEG Neurofeedback. <i>Frontiers in Physiology</i> , 2020, 11, 590503.	1.3	4
81	Personality Factors' Impact on the Structural Integrity of Mentalizing Network in Old Age: A Combined PET-MRI Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 552037.	1.3	4
82	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 349-374.	1.0	14
83	Neuroimaging in Movement Disorders. , 2019, , 1327-1361.		0
84	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
85	Gray Matter Densities in Limbic Areas and APOE4 Independently Predict Cognitive Decline in Normal Brain Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 157.	1.7	16
86	The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical candidates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1806-1816.	3.3	44
87	Higher nicotinic receptor availability in the cingulo-insular network is associated with lower cardiac parasympathetic tone. <i>Journal of Comparative Neurology</i> , 2019, 527, 3014-3022.	0.9	3
88	Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI. <i>Medical Oncology</i> , 2019, 36, 67.	1.2	13
89	Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1642-1651.	3.3	38
90	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). <i>NeuroImage: Clinical</i> , 2019, 23, 101846.	1.4	18

#	ARTICLE	IF	CITATIONS
91	Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. <i>Journal of Neurology</i> , 2019, 266, 1771-1781.	1.8	35
92	18F-FDG PET in Epilepsy. , 2019, , 65-76.		0
93	Morphological and Advanced Imaging of Epilepsy: Beyond the Basics. <i>Children</i> , 2019, 6, 43.	0.6	11
94	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	2.8	47
95	Does whole-body Patlak 18F-FDG PET imaging improve lesion detectability in clinical oncology?. <i>European Radiology</i> , 2019, 29, 4812-4821.	2.3	54
96	Clinical assessment of lesion detectability in dynamic whole-body PET imaging using compartmental and Patlak parametric mapping. , 2019, , .		0
97	Hippocampal Volume Loss, Brain Amyloid Accumulation, and APOE Status in Cognitively Intact Elderly Subjects. <i>Neurodegenerative Diseases</i> , 2019, 19, 139-147.	0.8	10
98	Amyloid Load, Hippocampal Volume Loss, and Diffusion Tensor Imaging Changes in Early Phases of Brain Aging. <i>Frontiers in Neuroscience</i> , 2019, 13, 1228.	1.4	9
99	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
100	Nicotinic receptor abnormalities as a biomarker in idiopathic generalized epilepsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 385-395.	3.3	14
101	PET/MRI in Brain Tumors. , 2018, , 185-222.		1
102	PET/MRI in Breast Cancer. , 2018, , 261-280.		1
103	Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study. <i>Journal of the Neurological Sciences</i> , 2018, 385, 17-21.	0.3	33
104	The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1210-1218.	0.4	12
105	123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy. <i>Clinical Nuclear Medicine</i> , 2018, 43, e33-e36.	0.7	14
106	Imaging pattern and histological features of Gorham-Stout Disease of the radius. <i>Journal of Solid Tumors</i> , 2018, 8, 20.	0.1	1
107	ICâ€Pâ€007: VISUAL RATING SCALES IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT CHARACTERIZED FOR AMYLOIDOSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P18.	0.4	0
108	P2â€370: AMYLOIDâ€PET FOR MYELIN IMAGING IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P836.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Quality Assurance of Small Animal Irradiation: Validation of a 3D-Printed Phantom for ^{67}Cu Quasi In-Vivo Dosimetry. International Journal of Radiation Oncology Biology Physics, 2018, 102, e476.	0.4	0
110	First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist ^{68}Ga -NODAGA-MJ9. EJNMMI Research, 2018, 8, 108.	1.1	25
111	Neuroimaging in Movement Disorders. , 2018, , 1-36.		2
112	Consolidation of a Learned Skill Correlates with Dopamine SPECT Uptake in Early Parkinson's Disease.		

#	ARTICLE	IF	CITATIONS
127	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 183-195.	1.5	85
128	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 214-227.	1.5	67
129	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	3.3	44
130	[P4â€“109]: EFFECT OF COGNITIVE RESERVE ON TAU BURDEN IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1299.	0.4	0
131	Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia With Lewy Bodies. <i>Clinical Nuclear Medicine</i> , 2017, 42, e96-e102.	0.7	26
132	The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al.. <i>Neurological Sciences</i> , 2017, 38, 1883-1884.	0.9	1
133	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464
134	[P4â€“491]: THE AMYPADâ€“X CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET. <i>Alzheimer's and Dementia</i> , 2017, 13, P1523.	0.4	0
135	Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 146.	1.7	25
136	Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	50
137	Patient-Specific Hybrid Whole-body PET Parametric Imaging From SpeedModulated Continuous Bed Motion Dynamic Data. , 2017, , .		1
138	Joint Optimization of Kinetic Modelling and CBM Acquisition Parameters in Hybrid Whole-Body Dynamic PET Imaging. , 2017, , .		2
139	FDG PET/MR Imaging in Major Neurocognitive Disorders. <i>Current Alzheimer Research</i> , 2017, 14, 186-197.	0.7	13
140	CO2BOLD assessment of moyamoya syndrome: Validation with single photon emission computed tomography and positron emission tomography imaging. <i>World Journal of Radiology</i> , 2016, 8, 887.	0.5	6
141	Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging. <i>Frontiers in Oncology</i> , 2016, 6, 73.	1.3	15
142	No more SWEDDs. <i>Movement Disorders</i> , 2016, 31, 1426-1426.	2.2	1
143	Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses. <i>NeuroImage: Clinical</i> , 2016, 12, 234-240.	1.4	41
144	Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 123-127.	1.2	10

#	ARTICLE	IF	CITATIONS
145	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
146	Severe early basal ganglia hypometabolism in neurodegeneration with brain iron accumulation. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1741-1742.	3.3	3
147	Dual-phase amyloid PET: hitting two birds with one stone. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1300-1303.	3.3	22
148	Scan without evidence of dopaminergic deficit: A 10-year retrospective study. Parkinsonism and Related Disorders, 2016, 31, 53-58.	1.1	38
149	Hybrid whole-body dynamic TOF PET imaging for simultaneous estimation of compartmental and patlak parametric maps from continuous bed motion data. , 2016, , .		4
150	Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome?. Parkinsonism and Related Disorders, 2016, 30, 62-66.	1.1	29
151	Re: Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimerâ€™s Disease (AD). Radiotherapy and Oncology, 2016, 118, 577-578.	0.3	8
152	Distinct spatiotemporal patterns for disease duration and stage in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 509-516.	3.3	8
153	Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCANâ€™) Using a Cohort of Individuals with Non-Degenerative Conditions. Molecular Imaging and Biology, 2016, 18, 302-312.	1.3	33
154	Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging. European Radiology, 2016, 26, 2297-2307.	2.3	45
155	Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates. Clinical Neurophysiology, 2016, 127, 150-155.	0.7	97
156	Continuous bed motion Vs. step-and-shoot acquisition on clinical whole-body dynamic and parametric PET imaging. , 2015, , .		10
157	Editorial (Thematic Issue: Is Ischemic Stroke an Inflammatory Disease?). Current Vascular Pharmacology, 2015, 13, 144-145.	0.8	0
158	Neuroimaging of the Vulnerable Plaque. Current Vascular Pharmacology, 2015, 13, 182-191.	0.8	3
159	Teaching Neuro <i>Images</i> : Drug-induced parkinsonism with asymmetrical putaminal DaT binding. Neurology, 2015, 84, e159.	1.5	2
160	Hybrid PET/MRI as a tool to detect brown adipose tissue: Proof of principle. Obesity Research and Clinical Practice, 2015, 9, 613-617.	0.8	9
161	A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1487-1491.	3.3	56
162	Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. Journal of the Neurological Sciences, 2015, 351, 127-132.	0.3	6

#	ARTICLE	IF	CITATIONS
163	All-in-one interictal presurgical imaging in patients with epilepsy: single-session EEG/PET/(f)MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1133-1143.	3.3	35
164	Qualitative and Quantitative Evaluation of Blob-Based Time-of-Flight PET Image Reconstruction in Hybrid Brain PET/MR Imaging. <i>Molecular Imaging and Biology</i> , 2015, 17, 704-713.	1.3	12
165	PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update. <i>Current Vascular Pharmacology</i> , 2015, 13, 209-217.	0.8	12
166	Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2015, 54, 211-216.	0.3	3
167	Brain Imaging. , 2015, , .		0
168	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. <i>NeuroImage: Clinical</i> , 2014, 6, 445-454.	1.4	172
169	Association of Adenosine Receptor Gene Polymorphisms and In Vivo Adenosine A1 Receptor Binding in The Human Brain. <i>Neuropsychopharmacology</i> , 2014, 39, 2989-2999.	2.8	29
170	First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 68-78.	3.3	46
171	Localization of the epileptogenic tuber with electric source imaging in patients with tuberous sclerosis. <i>Epilepsy Research</i> , 2014, 108, 267-279.	0.8	30
172	Subcortical and Deep Cortical Atrophy in Frontotemporal Dementia due to Granulin Mutations. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 95-102.	0.6	10
173	PET Radiotracers for Molecular Imaging in Dementia. <i>Current Radiopharmaceuticals</i> , 2014, 6, 215-230.	0.3	8
174	Neuroimaging of dementia in 2013: what radiologists need to know. <i>European Radiology</i> , 2013, 23, 3393-3404.	2.3	27
175	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 104-114.	3.3	170
176	Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns. <i>Child's Nervous System</i> , 2013, 29, 509-512.	0.6	12
177	Molecular neuroimaging with PET/MRI. <i>Clinical and Translational Imaging</i> , 2013, 1, 53-63.	1.1	14
178	TEP/IRM hybride en neuro-imagerie. <i>Medecine Nucleaire</i> , 2013, 37, 561-566.	0.2	0
179	Corrigendum to "In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease" [Parkinsonism Relat Disord 19 (2013) 47-52]. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 921.	1.1	1
180	Cholinergic activity correlates with reserve proxies in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2694.e13-2694.e18.	1.5	43

#	ARTICLE	IF	CITATIONS
181	Beyond cognitive reserve: Behavioural reserve hypothesis in Frontotemporal Dementia. Behavioural Brain Research, 2013, 245, 58-62.	1.2	21
182	Tracking the source of cerebellar epilepsy: Hemifacial seizures associated with cerebellar cortical dysplasia. Epilepsy Research, 2013, 105, 245-249.	0.8	19
183	Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 57-69.	1.1	54
184	InÂvivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 47-52.	1.1	185
185	Spinal Uptake Mimicking Metastasis in SPECT/CT Bone Scan in a Patient With Superior Vena Cava Obstruction. Clinical Nuclear Medicine, 2013, 38, 908-909.	0.7	14
186	Radiologic Patterns of Necrosis After Proton Therapy of Skull Base Tumors. Canadian Journal of Neurological Sciences, 2013, 40, 800-806.	0.3	8
187	Clinical Applications of Hybrid PET/MRI in Neuroimaging. Clinical Nuclear Medicine, 2013, 38, e13-e18.	0.7	92
188	Regions of Interestâ€‘Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia. Clinical Nuclear Medicine, 2013, 38, e112-e117.	0.7	33
189	Peripheral Nerves, Tumors, and Hybrid PET-MRI. Clinical Nuclear Medicine, 2013, 38, e40-e42.	0.7	7
190	[11C]-MP4A PET Cholinergic Measurements in Amnesic Mild Cognitive Impairment, Probable Alzheimer's Disease, and Dementia with Lewy Bodies: A Bayesian Method and Voxel-Based Analysis. Journal of Alzheimer's Disease, 2012, 31, 387-399.	1.2	41
191	Individual Detection of Patients with Parkinson Disease using Support Vector Machine Analysis of Diffusion Tensor Imaging Data: Initial Results. American Journal of Neuroradiology, 2012, 33, 2123-2128.	1.2	99
192	Nature versus Nurture in Frontotemporal Lobar Degeneration: the Interaction of Genetic Background and Education on Brain Damage. Dementia and Geriatric Cognitive Disorders, 2012, 33, 372-378.	0.7	20
193	18F-FDG PET/CT and Contrast-Enhanced CT in a One-Stop Diagnostic Procedure. Clinical Nuclear Medicine, 2012, 37, 453-459.	0.7	14
194	FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2012, 28, 941-950.	1.2	16
195	Education and occupation provide reserve in both ApoE Î¼4 carrier and noncarrier patients with probable Alzheimerâ€™s disease. Neurological Sciences, 2012, 33, 1037-1042.	0.9	51
196	Changes in brain glucose metabolism in subthalamic nucleus deep brain stimulation for advanced parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 770-774.	1.1	11
197	Applications cliniques de lâ€™imagerie hybride TEP-IRM. Medecine Nucleaire, 2012, 36, 605-614.	0.2	2
198	FDG PETâ€™CT in detection of diaphragmatic metastasis of dedifferentiated liposarcoma: A case report. European Journal of Radiology Extra, 2011, 77, e35-e38.	0.1	2

#	ARTICLE	IF	CITATIONS
199	Adenosine A1 receptors in human brain and transfected CHO cells: Inhibition of [3H]CPFPX binding by adenosine and caffeine. <i>Neuroscience Letters</i> , 2011, 487, 415-420.	1.0	9
200	Subcortical and deep cortical atrophy in Frontotemporal Lobar Degeneration. <i>Neurobiology of Aging</i> , 2011, 32, 875-884.	1.5	63
201	A PET-MRI Case of Corticocerebellar Diaschisis After Stroke. <i>Clinical Nuclear Medicine</i> , 2011, 36, 821-825.	0.7	7
202	90Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1744-1745.	3.3	18
203	In vivo evidence for GABA _A receptor changes in the sensorimotor system in primary dystonia. <i>Movement Disorders</i> , 2011, 26, 852-857.	2.2	61
204	Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 108-114.	0.6	13
205	Disorganization of anatomical connectivity in obsessive compulsive disorder: A multi-parameter diffusion tensor imaging study in a subpopulation of patients. <i>Neurobiology of Disease</i> , 2010, 37, 468-476.	2.1	103
206	Revisiting Brain Reserve Hypothesis in Frontotemporal Dementia: Evidence from a Brain Perfusion Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 130-135.	0.7	51
207	The behavioural features of fatal familial insomnia: A new Italian case with pathological verification. <i>Sleep Medicine</i> , 2009, 10, 581-585.	0.8	10
208	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. <i>Neurobiology of Disease</i> , 2008, 31, 102-109.	2.1	24
209	In vivo PET study of 5HT _{2A} serotonin and D ₂ dopamine dysfunction in drug-naïve obsessive-compulsive disorder. <i>NeuroImage</i> , 2008, 42, 306-314.	2.1	178
210	Education and occupation as proxies for reserve in aMCI converters and AD. <i>Neurology</i> , 2008, 71, 1342-1349.	1.5	201
211	The logopenic/phonological variant of primary progressive aphasia. <i>Neurology</i> , 2008, 71, 1227-1234.	1.5	602
212	Brain Magnetic Resonance Imaging Structural Changes in a Pedigree of Asymptomatic Progranulin Mutation Carriers. <i>Rejuvenation Research</i> , 2008, 11, 585-595.	0.9	87
213	White Matter Changes in Corticobasal Degeneration Syndrome and Correlation With Limb Apraxia. <i>Archives of Neurology</i> , 2008, 65, 796-801.	4.9	83
214	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007, 68, 875-876.	1.5	46
215	Evidence of White Matter Changes on Diffusion Tensor Imaging in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2007, 64, 246.	4.9	123
216	Reversible nonfluent aphasia and left frontal hypoperfusion during topiramate treatment. <i>Epilepsy and Behavior</i> , 2007, 10, 192-194.	0.9	14

#	ARTICLE	IF	CITATIONS
217	Edge Tracking of subjective contours in Biomedical Imaging., 2007, , .		0
218	Persistent Autobiographical Amnesia: A Case Report. Behavioural Neurology, 2007, 18, 13-17.	1.1	11
219	PET evidence of central GABAergic changes in stiff-person syndrome. Movement Disorders, 2007, 22, 1030-1033.	2.2	22
220	Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiology of Aging, 2006, 27, 24-31.	1.5	139
221	Positron emission tomography changes in PARK1 mutation. Movement Disorders, 2006, 21, 127-130.	2.2	6
222	Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. Journal of Neurology, 2005, 252, 1359-1362.	1.8	34
223	Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 425-426.	0.9	18